Obesity Management

Explore the latest findings on GLP-1 drugs, including their impact on Alzheimer's and promising results for type 1 diabetes treatment.

Children with MASLD were more likely to live in neighborhoods with greater socioeconomic and environmental disadvantage than those with overweight or obesity but without MASLD.

Bariatric surgery, particularly sleeve gastrectomy, may improve survival and kidney transplant access in older adults with obesity and ESKD.

AASLD 2025 data show mazdutide significantly reduces liver fat, ALT, AST, and insulin resistance in patients with obesity, and MASLD

Eli Lilly and Company’s investigative therapy provided effective and safe weight loss treatment with limited adverse events.

The investigative GLP-1/GCG dual receptor agonist led to a higher proportion of participants achieving HbA1c and body weight improvements from baseline.

A post hoc analysis of the PLIS study has highlighted the comparative effectiveness of glucose levels in achieving prediabetes remission.

Despite bearing a greater obesity burden, Black, Hispanic, and American Indian/Native individuals are underrepresented in GLP-1 RA RCTs for weight loss.

Although no direct correlation can be drawn, these findings suggest a possible ocular benefit from GLP-1 RAs compared to other weight loss drugs.

GLP-1 RAs may offer benefits beyond adiposity reduction in patients with atherosclerotic cardiovascular disease.

CHEST 2025 data suggest OSA is an "effect modifier" on the mortality benefit of GLP-1 receptor agonists in patients co-diagnosed with type 2 diabetes.

This episode covers the upcoming glucose monitor Biolinq Shine, the Insulin Icodec FDA resubmission, and the end of Eli Lilly's work in T2D.

Celebrate 150 episodes of Diabetes Dialogue as hosts reflect on advancements in diabetes technology and impactful discussions in patient care.

Yale researchers reveal that 17 million U.S. adolescents and young adults qualify for GLP-1RA therapy, highlighting barriers to access and insurance coverage.

Despite the global prevalence of hypercholesterolemia, only 11% of children receive lipid screening, leaving many cases undiagnosed.

This episode highlights the results of the ATTAIN-1 and STEP UP clinical trials, examining the potential of their respective GLP-1 RA subjects.

Semaglutide exhibited a 57% reduction in major adverse cardiovascular events compared to tirzepatide in patients with CVD with no prior history of diabetes.

Hosts explore the latest findings on GLP-1 medications, semaglutide and tirzepatide, from ESC Congress 2025.

A 30-week trial found weekly semaglutide reduced HbA1c while improving physical quality of life in patients on antipsychotics.

An audio recap of the top 5 stories in healthcare news from the week of 08/24-08/30.

Stay updated with the latest healthcare breakthroughs, including FDA news, vaccine guidelines, and orforglipron data, in this week's essential news roundup.

Orforglipron met the primary and all key secondary endpoints in patients with obesity/overweight and type 2 diabetes, supporting global regulatory submissions.

The cross-sectional analysis of NHANES data highlights obesity and overweight’s influence on the development of obesity-related conditions in US youth.

Semaglutide 2.4 mg use was linked to lower medical costs and inpatient resource utilization among patients with overweight or obesity and heart failure.